This is a working overview of post-marketing surveillance, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-07-22. Anything still debated is marked as such rather than presented as settled.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.
Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic cyclic heptapeptide | Analog of alpha-MSH with an internal lactam bridge |
| Molecular weight | Approximately 1024 daltons | Free base value; salt forms differ |
| Appearance | White to off-white powder | Usually supplied as a lyophilized solid |
| Solubility | Freely soluble in water | Poorly soluble in nonpolar solvents |
| Typical storage | −20 °C, dry, protected from light | Repeated freeze-thaw cycles degrade peptides |
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
=== Private members === Private members include individuals such as researchers, scientists, industrial practitioners, journalists or professors with extensive expertise, passion or active in fields related to the refrigeration sector.
=== Separation Processes === King wrote the book Separation Processes in 1971. In the book, King presented that each of the separation processes (distillation, extraction, absorption, etc.) is a special case of a unified technology that can be described by a general set of quantitative principles. Before that, the standard separation operations were considered to be separate topics within the category of unit operations, with separate methodologies. The book was revised for a second edition in 1980. After the book went out of print, King secured the copyright back from McGraw-Hill and put it on eScholarship, where it is available open-access.
The plan was that Johannesburg would revolt and seize the Boer armoury in Pretoria. Jameson and his force would dash across the border to Johannesburg to "restore order" and with control of Johannesburg would control the gold fields. However, while Jameson waited for the insurrection to begin, differences arose within the Reform Committee and between Johannesburg Uitlander reformers regarding the form of government to be adopted after the coup. At a point, certain reformers contacted Jameson to inform him of the difficulties and advised him to stand down. Jameson, with 600 restless men and other pressures, became frustrated by the delays and, believing that he could spur the reluctant Johannesburg reformers to act, decided to go ahead. He sent a telegram on 28 December 1895 to Rhodes warning him of his intentions – "Unless I hear definitely to the contrary, shall leave to-morrow evening" – and on the very next day sent a further message, "Shall leave to-night for the Transvaal". However, the transmission of the first telegram was delayed, so that both arrived at the same time on the morning of 29 December, and by then Jameson's men had cut the telegraph wires and there was no way of recalling him. On 29 December 1895, Jameson's armed column crossed into the Transvaal and headed for Johannesburg. They hoped that this would be a three-day dash to Johannesburg before the Boer commandos could mobilise, and would trigger an uprising by the Uitlanders.
=== High-pressure reserve gas === An alternative to a low-pressure compressor for gas supply is high-pressure gas storage cylinders feeding through a pressure regulator which will be set to the required supply pressure for the depth and equipment in use. In practice HP storage may be used for either reserve gas supply or both main and reserve gas supplies to a gas panel. High-pressure bulk cylinders are quiet in operation and provide gas of known quality (if it has been tested). This allows the relatively simple and reliable use of nitrox mixtures in surface-supplied diving. Bulk cylinders are also quiet in operation compared to a low-pressure compressor, but have the obvious limitation of amount of gas available. The usual configurations for surface-supplied bulk gas storage are large single cylinders of around 50 litres water capacity, often referred to as "J"s or "bombs", "quads", which are a group (sometimes, but not necessarily four in number) of similar cylinders mounted on a frame and connected together to a common supply fitting, and "kellys" which are a group of "gas storage tubes" (long large volume seamless transportable gas storage pressure vessels, with water capacity between 150 litres (5.3 cu ft) and 3,000 litres (110 cu ft)) usually mounted in a container frame or trailer, and usually connected together to a manifold with a common connection fitting.
Sources: en.wikipedia.org
May 13–15 – President Trump makes a state visit to China and meets with Chinese leader Xi Jinping. May 13 – The U.S. Senate confirms Kevin Warsh as the Chair of the Federal Reserve in a 54–45 vote. Warsh will succeed Jerome Powell at the end of the latter's term. May 14 Federal employees sue USDA and Secretary Brooke Rollins on First Amendment grounds over proselytizing Christian messaging in work emails. Mike Banks resigns as U.S. Border Patrol Chief, saying he wanted to spend time with family. Bank's resignation came weeks after the Washington Examiner alleged that he engaged in sex tourism in Colombia and Thailand. May 16 – 2026 Long Island Rail Road strike: Five unions representing over 3,500 workers for the Long Island Rail Road, the largest commuter rail system in North America, go on strike to negotiate a new contract with the Metropolitan Transportation Authority in New York City. May 18 – Five people, including two gunmen, are killed in a mass shooting at a mosque in San Diego, California. May 18–19 – The DOJ announces they reached a settlement with the Internal Revenue Service to resolve Trump's $10 billion lawsuit regarding the 2020 leak of his tax returns to The New York Times. Trump drops the lawsuit but will receive a $1.776 billion "anti-weaponization fund" to give to people who were prosecuted by the Biden administration. A day later, the DOJ reveals that the settlement terms include that the IRS is "forever barred and precluded" from investigating past tax returns filed by President Trump, his family and his businesses. May 19 – U.S.
A 2016 paper describes the efforts of how ansuvimab was originally developed as part of research efforts led by Dr. Nancy Sullivan at the United States National Institutes of Health Vaccine Research Center and Dr. J. J. Muyembe-Tamfum from the Institut National de Recherche Biomedicale (INRB) in the Democratic Republic of Congo. This collaborative effort also involved researchers from Institute of Biomedical Research and the United States Army Medical Research Institute of Infectious Diseases. A survivor from the 1995 outbreak of Ebola virus disease in Kikwit, Democratic Republic of Congo donated blood to the project that began roughly ten years after they had recovered. Memory B cells isolated from the survivor's blood were immortalized, cultured and screened for their ability to produce monoclonal antibodies that reacted with the glycoprotein of Ebola virus. Ansuvimab was identified from one of these cultures and the antibody heavy and light chain gene sequences were sequenced from the cells. These sequences were then cloned into recombinant DNA plasmids and purified antibody protein for initial studies was produced in cells derived from HEK 293 cells.
On March 22, 2023, Valve announced Counter-Strike 2, which utilizes the Source 2 game engine. It was originally announced as a free upgrade to Global Offensive with a summer 2023 release date. On September 1, 2023, it was released as a limited beta, and the game replaced Global Offensive on September 27.
=== A10BB Sulfonylureas === A10BB01 Glibenclamide A10BB02 Chlorpropamide A10BB03 Tolbutamide A10BB04 Glibornuride A10BB05 Tolazamide A10BB06 Carbutamide A10BB07 Glipizide A10BB08 Gliquidone A10BB09 Gliclazide A10BB10 Metahexamide A10BB11 Glisoxepide A10BB12 Glimepiride A10BB31 Acetohexamide
Putin would have gone in anyway." According to Fried, it was probably the intervention of US president George W. Bush that forced Putin to halt hostilities in Georgia and the reset policy of Obama administration was a mistake.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.
Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.
No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.
The lyophilised solid is best kept cold, dry and dark, typically at minus twenty degrees Celsius. Moisture and repeated warming cycles are the main causes of degradation. Solutions prepared from the powder are less stable and are normally used quickly.